{"id":"NCT02163499","sponsor":"ZS Pharma, Inc.","briefTitle":"Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months","officialTitle":"Multicenter, Multi-Dose, Open-Label Maintenance of Long-Term Safety and Efficacy of Sodium Zirconium Cyclosilicate (ZS) in Hyperkalemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06-30","primaryCompletion":"2016-11-30","completion":"2016-11-30","firstPosted":"2014-06-13","resultsPosted":"2018-06-27","lastUpdate":"2018-06-27"},"enrollment":751,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Hyperkalemia"],"interventions":[{"type":"DRUG","name":"Sodium Zirconium Cyclosilicate","otherNames":["ZS"]}],"arms":[{"label":"Sodium Zirconium Cyclosilicate","type":"EXPERIMENTAL"}],"summary":"The Open-Label Maintenance Study contains an Acute Phase, in which subjects will be dosed with ZS 10 g three times daily (tid) for 24 to 72 hours, followed by a long-term Maintenance Phase.","primaryOutcome":{"measure":"Percent of Participants With Restoration of Normal Serum Potassium (S-K) Values (3.5 to 5.0 mmol/L, Inclusive) at the End of the Acute Phase","timeFrame":"72 Hours","effectByArm":[{"arm":"Percentage","deltaMin":77.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":14},"locations":{"siteCount":50,"countries":["United States","Australia","Germany","Netherlands","Romania","South Africa","United Kingdom"]},"refs":{"pmids":["32030422"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":751},"commonTop":["Hypertension","Oedema peripheral","Nausea","Urinary tract infection","Constipation"]}}